参考文献/References:
[1] Miranda-Filho A,Lortet-Tieulent J,Bray F,et al.Thyroid cancer incidence trends by histology in 25 countries:a population-based study[J].Lancet Diabetes Endocrinol,2021,9(4):225-234.DOI:10.1016/S2213-8587(21)00027-9.
[2] Abdullah MI,Junit SM,Ng KL,et al.Papillary thyroid cancer:genetic alterations and molecular biomarker investigations[J].Int J Med Sci,2019,16(3):450-460.DOI:10.7150/ijms.29935.
[3] Mao M,Huang RZ,Zheng J,et al.OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer[J].Cancer Med,2021,10(2):728-736.DOI:10.1002/cam4.3640.
[4] Means C,Clayburgh DR,Maloney L,et al.Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status[J].Head Neck,2019,41(8):2636-2646.DOI:10.1002/hed.25740.
[5] Bai Y,Guo T,Huang X,et al.In papillary thyroid carcinoma,expression by immunohistochemistry of RAFV600E,PD-L1,and PD-1 is closely related[J].Virchows Arch,2018,472(5):779-787.DOI:10.1007/s00428-018-2357-6.
[6] Gogali F,Paterakis G,Rassidakis GZ,et al.CD3(-)CD16(-)CD56(bright)immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer[J].Thyroid,2013,23(12):1561-1568.DOI:10.1089/thy.2012.0560.
[7] Gulubova MV,Ivanova KV.The Expression of tumor-associated macrophages and multinucleated giant cells in papillary thyroid carcinoma[J].Open Access Maced J Med Sci,2019,7(23):3944-3949.DOI:10.3889/oamjms.2019.715.
[8] Pan J,Ye F,Yu C,et al.Papillary thyroid carcinoma landscape and Its immunological link with hashimoto thyroiditis at single-cell resolution[J].Front Cell Dev Biol,2021,9:758339.DOI:10.3389/fcell.2021.758339.
[9] Binnewies M,Roberts EW,Kersten K,et al.Understanding the tumor immune microenvironment(TIME)for effective therapy[J].Nat Med,2018,24(5):541-550.DOI:10.1038/s41591-018-0014-x.
[10] Na KJ,Choi H.Immune landscape of papillary thyroid cancer and immunotherapeutic implications[J].Endocr Relat Cancer,2018,25(5):523-531.DOI:10.1530/ERC-17-0532.
[11] Cunha LL,Nonogaki S,Soares FA,et al.Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis[J].Endocr Pathol,2017,28(4):369-372.DOI:10.1007/s12022-017-9495-2.
[12] Xie Z,Li X,He Y,et al.Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment[J].Front Endocrinol(Lausanne),2020,11:570604.DOI:10.3389/fendo.2020.570604.
[13] Fagin JA,Wells SA Jr.Biologic and clinical perspectives on thyroid cancer[J].N Engl J Med,2016,375(11):1054-1067.DOI:10.1056/NEJMra1501993.
[14] Han J,Hong Y,Lee Y S.PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients[J].J Pathol Transl Med,2017,51(1):40-48.DOI:10.4132/jptm.2016.08.31.
[15] Shi X,Yu PC,Lei BW,et al.Association between programmed Death-Ligand 1 expression and clinicopathological characteristics,structural recurrence,and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J].Thyroid,2019,29(9):1269-1278.DOI:10.1089/thy.2019.0079.
[16] Zalatnai A.Molecular aspects of stromal-parenchymal interactions in malignant neoplasms[J].Curr Mol Med,2006,6(6):685-693.DOI:10.2174/156652406778195053.
[17] Koperek O,Bergner O,Pichlhöfer B,et al.Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene[J].J Pathol,2011,225(1):63-72.DOI:10.1002/path.2926.
[18] Maio M,Coral S,Sigalotti L,et al.Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma:expression and humoral response to NY-ESO-1[J]. J Clin Endocrinol Metab,2003,88(2):748-754.DOI:10.1210/jc.2002-020830.
[19] Yang J,Barletta JA.Anaplastic thyroid carcinoma[J].Semin Diagn Pathol,2020,37(5):248-256.DOI:10.1053/j.semdp.2020.06.005.
[20] Gunda V,Gigliotti B,Ashry T,et al.Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer[J].Int J Cancer,2019,144(9):2266-2278.DOI:10.1002/ijc.32041.
[21] Cristinziano L,Modestino L,Loffredo S,et al.Anaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils[J].J Immunol,2020,204(5):1362-1372.DOI:10.4049/jimmunol.1900543.
[22] Duquette M,Sadow PM,Lawler J,et al.Thrombospondin-1 silencing Down-Regulates integrin expression levels in human anaplastic thyroid cancer cells with RAFV600E:new insights in the host tissue adaptation and homeostasis of tumor microenvironment[J].Front Endocrinol(Lausanne),2020,11:596223.DOI: 10.3389/fendo.2020.596223.
[23] Gunda V,Gigliotti B,Ndishabandi D,et al.Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J].Br J Cancer,2018,119(10):1223-1232.DOI:10.1038/s41416-018-0296-2.
[24] Passaro C,Borriello F,Vastolo V,et al.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma[J].Oncotarget,2016,7(2):1500-1515.DOI:10.18632/oncotarget.6430.
[25] Amrenova A,Suzuki K,Saenko V,et al.Cell competition between anaplastic thyroid cancer and normal thyroid follicular cells exerts reciprocal stress response defining tumor suppressive effects of normal epithelial tissue[J].PLoS One,2021,16(4):e249059.DOI:10.1371/journal.pone.0249059.
[26] Caillou B,Talbot M,Weyemi U,et al.Tumor-associated macrophages(TAMs)form an interconnected cellular supportive network in anaplastic thyroid carcinoma[J].PLoS One,2011,6(7):e22567.DOI:10.1371/journal.pone.0022567.
[27] Cunha LL,Marcello MA,Ward LS.The role of the inflammatory microenvironment in thyroid carcinogenesis[J].Endocr Relat Cancer,2014,21(3):R85-R103.DOI:10.1530/ERC-13-0431.
[28] Chalan P,Di Dalmazi G,Pani F,et al.Thyroid dysfunctions secondary to cancer immunotherapy[J].J Endocrinol Invest,2018,41(6):625-638.DOI:10.1007/s40618-017-0778-8.
相似文献/References:
[1]于亚静 杨彩哲 关小宏 王良宸 吴石白 刘明 肖黎 张妲 刘朝阳.甲状腺癌与桥本甲状腺炎及其他相关危险因素的研究[J].国际内分泌代谢杂志,2015,(01):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
Yu Yajing*,Yang Caizhe,Guan Xiaohong,et al.Relationship between thyroid carcinoma, Hashimoto′s thyroiditis and other related risk factors[J].International Journal of Endocrinology and Metabolism,2015,(01):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
[2]李兴佳 曹萌 刘超.自噬与甲状腺癌的关系[J].国际内分泌代谢杂志,2015,(01):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
Li Xingjia,Cao Meng,Liu Chao..Relationship between autophagy and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2015,(01):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
[3]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(01):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[4]孟祥慧,徐书杭,蔡可英,等.肥胖与甲状腺癌：临床新启示[J].国际内分泌代谢杂志,2014,(02):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
Meng Xianghui*,Xu Shuhang,Cai Keying,et al.Obesity and thyroid cancer: a new clinical implication[J].International Journal of Endocrinology and Metabolism,2014,(01):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
[5]孙洪平,陈国芳,曹雯,等.糖尿病与甲状腺癌关系的研究进展[J].国际内分泌代谢杂志,2014,(02):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
Sun Hongping,Chen Guofang,Cao Wen,et al.Diabetes and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2014,(01):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
[6]于亚静,杨彩哲,关小宏,等.桥本甲状腺炎和甲状腺癌的关系[J].国际内分泌代谢杂志,2014,(03):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
Yu Yajing,Yang Caizhe,Guan Xiaohong,et al.Relationship between Hashimoto's thyroiditis and thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2014,(01):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
[7]张倍宁 闫如意 周金莲 崔彦.甲状腺癌中miRNA的表达及作用[J].国际内分泌代谢杂志,2018,38(03):167.[doi:10.3760/cma.j.issn.1673-4157.2018.03.006]
Zhang Beining*,Yan Ruyi,Zhou Jinlian,et al.Expression and function of miRNA in thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2018,38(01):167.[doi:10.3760/cma.j.issn.1673-4157.2018.03.006]
[8]任秀利 柳艳萍 宋富军 王亭 倪明 张平平 刘明法.1990—2015年天津市滨海新区甲状腺癌
流行特征及长期发病趋势分析[J].国际内分泌代谢杂志,2020,40(02):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
Ren Xiuli,Liu Yanping,Song Fujun,et al.Epidemiological characteristics and long-term trends of thyroid cancer in Binhai New Area of Tianjin from 1990 to 2015[J].International Journal of Endocrinology and Metabolism,2020,40(01):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
[9]井超,王旭东.免疫治疗在甲状腺癌中的研究进展[J].国际内分泌代谢杂志,2021,41(05):459.[doi:10.3760/cma.j.cn121383-20210624-06069]
Jing Chao,Wang Xudong..Research progress of immunotherapy in thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(01):459.[doi:10.3760/cma.j.cn121383-20210624-06069]
[10]胡欣,褚晓秋,陈国芳,等.欧洲甲状腺学会/欧洲心血管介入放射学会《甲状腺癌微创治疗的临床实践指南》解读:审时与度势[J].国际内分泌代谢杂志,2023,43(03):278.[doi:10.3760/cma.j.cn121383-20211126-11069]
Hu Xin,Chu Xiaoqiu,Chen Guofang,et al.[J].International Journal of Endocrinology and Metabolism,2023,43(01):278.[doi:10.3760/cma.j.cn121383-20211126-11069]